ResearchMoz

Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Transparency Market Research
Published Date » 2015-04-28
No. Of Pages » 104
 
 
   
 The global peptide therapeutics market report provides detailed analysis, market size, and forecast for therapeutic peptides approved for various indications. The market is studied from four major perspectives: applications, route of administration, marketing status, and geography. Application segments of the global peptide therapeutics market have been further sub-segmented by major branded peptide drugs approved by regulatory authorities across the globe. Various applications considered in the report include metabolic disorders, hematological disorders, cancer, cardiovascular disorders, central nervous system disorders, infection, gastrointestinal disorders, respiratory disorders, acromegaly, and others. Market size and forecast for leading drugs such as Angiomax,...

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations
1.5 Assumptions and Stipulations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
2.2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)

Chapter 3 Global Peptide Therapeutics Market Overview
3.1 Introduction
3.2 Emerging Trends in Peptide Therapeutics Market
3.2.1 Trends in Peptide Manufacturing Technology
3.2.2 Trends in Peptide API Supply
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides
3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth
3.3.1.3 Technological advancements have reduced total production cost of peptides
3.3.2 Restraints
3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers
3.3.2.2 Lack of regulatory standards
3.3.3 Opportunities
3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period
3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth
3.4 Regulatory Scenario
3.5 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyer
3.5.3 Threat of Substitutes
3.5.4 Threat of New Entrants
3.5.5 Competitive Rivalry
3.6 Event Impact Analysis
3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
3.8 Market Share Analysis

Chapter 4 Global Peptide Therapeutics Market, by Applications
4.1 Introduction
4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million)
4.2 Cancer
4.2.1 Global Cancer Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.2.2 Zoladex (goserelin)
4.2.3 Velcade (bortezomib)
4.2.4 Lupron/ Enantone/ Eligard (leuprorelin)
4.2.5 Others
4.3 Cardiovascular
4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.3.2 Angiomax (bivalirudin)
4.3.3 Integrilin (eptifibatide)
4.4 Central Nervous System
4.4.1 Global Central Nervous System Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.4.2 Copaxone (glatiramer)
4.5 Metabolic Disorders
4.5.1 Global Metabolic Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.5.2 Victoza (liraglutide)
4.5.3 Byetta (exenatide)
4.5.4 Others
4.6 Infection
4.6.1 Global Infection Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.6.2 Incivek (telaprevir)
4.6.3 Victrelis (boceprevir)
4.7 Hematological Disorders
4.7.1 Global Hematological Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.7.2 Firazyr (icatibant)
4.7.3 Kalbitor (ecallantide)
4.8 Gastrointestinal Disorders
4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.8.2 Gattex (teduglutide)
4.8.3 Linzess (linaclotide)
4.9 Respiratory Disorders
4.9.1 Global Respiratory Disorders Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
4.10 Acromegaly
4.10.1 Global Acromegaly Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.11 Other Applications
4.11.1 Global Other Applications Peptide Therapeutics market  Revenue, 2012 - 2020 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
5.2 Parenteral Route of Administration
5.2.1 Global Peptide Therapeutics Market  Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
5.3 Oral Route of Administration
5.3.1 Global Peptide Therapeutics Market  Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million)

Chapter 6 Global Peptide Therapeutics Market, by Marketing Status
6.1 Introduction
6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
6.2 Branded Peptide Therapeutics
6.2.1 Global Branded Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
6.3 Generic Peptide Therapeutics
6.3.1 Global Generic Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)

Chapter 7 Global Peptide Therapeutics Pipeline Overview
7.1 Introduction
7.1.1 Global Peptide Therapeutics Pipeline Overview

Chapter 8 Global Peptide Therapeutics Market, by Geography
8.1 Introduction
8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
8.2 North America
8.2.1 North America Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.3 Europe
8.3.1 Europe Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.5 Rest of the World
8.5.1 Rest of the World Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)

Chapter 9 Recommendations
9.1 Rigorous research and development (R&D) would yield new products
9.2 Facility expansion in emerging economies
9.3 Rapid inorganic growth through acquisitions

Chapter 10 Company Profiles
10.1 Amgen, Inc.
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.1.5 Recent Developments
10.2 AstraZeneca plc
10.2.1 Company Overview
10.2.2 Financial Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.2.5 Recent Developments
10.3 Bachem Holding AG
10.3.1 Company Overview
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.3.5 Recent Developments
10.4 CordenPharma International GmbH
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.4.5 Recent Developments
10.5 Eli Lilly and Company
10.5.1 Company Overview
10.5.2 Financial Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.5.5 Recent Developments
10.6 Ipsen S.A.
10.6.1 Company Overview
10.6.2 Financial Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.6.5 Recent Developments
10.7 Lonza Group Ltd.
10.7.1 Company Overview
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.7.5 Recent Developments
10.8 Merck & Co., Inc.
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.8.5 Recent Developments
10.9 Novartis AG
10.9.1 Company Overview
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.9.5 Recent Developments
10.10 Novo Nordisk A/S
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.10.5 Recent Developments
10.11 PolyPeptide Group
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.11.5 Recent Developments
10.12 Roche Holdings AG
10.12.1 Company Overview
10.12.2 Financial Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.12.5 Recent Developments
10.13 Sanofi
10.13.1 Company Overview
10.13.2 Financial Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.13.5 Recent Developments
10.14 Takeda Pharmaceutical Company Limited
10.14.1 Company Overview
10.14.2 Financial Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.14.5 Recent Developments
10.15 Teva Pharmaceutical Industries Ltd.
10.15.1 Company Overview
10.15.2 Financial Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.15.5 Recent Developments

List of Tables


TABLE 1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
TABLE 2 Event Impact Analysis: Global Peptide Therapeutics Market
TABLE 3 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million)
TABLE 4 Global Cancer Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 5 Global Cardiovascular Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 6 Global Metabolic Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 7 Global Infection Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 8 Global Hematological Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 9 Global Gastrointestinal Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 10 Global Acromegaly Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 11 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
TABLE 12 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
TABLE 13 Global Peptide Therapeutics Market Pipeline Overview
TABLE 14 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

List of Figures


FIG. 1 Peptide Therapeutics Market Segmentation
FIG. 2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)
FIG. 3 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market
FIG. 4
FIG. 5 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
FIG. 6 Market Share Analysis of Global Peptide Therapeutics Market, by Key Players, 2013 (Value %)
FIG. 7 Global Central Nervous System  Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 9 Global Other Applications Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 10 Global Peptide Therapeutics Market  Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
FIG. 11 Global Peptide Therapeutics Market  Revenue, by Oral Route of Administration, 2012 - 2020  (USD Million)
FIG. 12 Global Branded Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
FIG. 13 Global Generic Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
FIG. 14 North America Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 15 Europe Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 16 Asia Pacific Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 17 Rest of the World Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 18 Amgen, Inc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 19 AstraZeneca plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 20 Bachem Holding AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 21 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 22 Ipsen S.A.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 23 Lonza Group Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 24 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 25 Novartis AG Annual Revenue: 2011 – 2013 (USD Million)
FIG. 26 Novo Nordisk A/S Annual Revenue: 2011 – 2013 (USD Million)
FIG. 27 Roche Holdings AG: Annual Revenue: 2011 – 2013 (USD Million)
FIG. 28 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 29 Takeda Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million)
FIG. 30 Teva Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million)

Upcoming Reports:

Hysterectomy Alternatives Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Hysterectomy is the process where complete or partial uterus is removed from the women’s body by the gynecologist. In complete uterus removal, fundus, cervix and body of the uterus are removed whereas in partial only body of the uterus is excised.Hysterectomy is performed when a women is suffering from fibroids, uterine prolapse, endometriosis, chronic pelvic pain, vaginal bleeding and cancer of uterus, ovaries and cervix. It has been observed in U.S. that 1 out of 3 women are undergoing hysterectomy annually. Hysterectomy has various issues such as hormonal imbalance,...
Personal Hygiene Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The personal hygiene market is growing significantly owing to the increasing interest of people for personal care and health concerns. Many new manufacturers are making their way into the market as a result of the rising trend of personal care products in growing economies.  Personal hygiene is the first step toward good grooming and better health. There are a variety of illnesses that can be prevented just by improving personal hygiene. Some illnesses are not a result of poor personal hygiene, but improving the standards of hygiene will control adverse conditions. ...
IV Therapy and Vein Access Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
The global market for intravenous and vein access devices encompasses a variety of devices such as peripheral venous access, central venous access, ambulatory infusion, enteral feeding, syringe infusion, implantable pumps and diabetes insulin infusion devices. These devices are used for intravenous administration of drugs, fluid infusion, blood sampling, venous pressure monitoring, blood and transfusion. Implantable ports, catheters, syringes, needles and needless connectors are examples of various intravenous therapy and vein access devices. Some of the commercially available...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Keeps High Hopes from Asia Pacific
May 27, 2015  
Ford Motor Company is continuing to make investments heavily in the mainland China, despite the company is getting signs showing a mild slowdown, which has caused the automobile manufacturer to make some small cut in the productions of vehicles. The Asia Pacific president of Ford, David Schoch, has declined to give out any details and of which all models were affected in this mentioned cuts,...
Tata Motors to Face Some Shrink in Profits Figures Due to the Declining Demand of Jaguar Land Rover in China
May 27, 2015  
The quarterly profits of Tata Motors went down, owing to the declining demand for Jaguar Land Rover vehicles in China. On Tuesday, Tata Motors informed that the net income fell around 56% to US$269 million (17.2 billion rupees) in the first quarter that ended in March, from 39.2 billion rupees that was in the previous year. The profits at the Jaguar Land Rover segments went down 33% to...
Changsha Unit of Volkswagen Group Launches Its First Product into the Market
May 27, 2015  
Just a couple of days back, the Volkswagen Group’s recent active production facility launched its very first car off the line. The Changsha plant of Volkswagen is anticipated to boost the production capacity of the German automaker in the Asia Pacific market by around 300,000 units every year. According to the Global Times on 24th of May, a brand new sedan named - Lavida arrived...
China Will Now Have its Own Forrest Gump Restaurant
May 27, 2015  
Last week, the city of Changchun in China witnessed the inauguration of the country’s very own Forrest Gump Restaurant. China is renowned across the globe as the hotbed of the most innovative and quirky restaurants and eateries, and many of them recreate the world of the various television show and film. The country already has a “Friends” themed restaurant that hails its...
Hormel Acquired the Stakes of Applegate Farms
May 27, 2015  
It was recently announced by a spokesperson from Hormel Foods that the company has paid a whopping US$775 million to take over the stakes of the renowned processed meats maker, Applegate Farms. The deal according to many will be the latest one initiated by a market leader to purchase the smaller rivals in the food industry.  When questioned about the reason behind the decision of...